Released Mar 21, 2019, after the close
10-K filed Mar 22, 2019, 81 days after period end · 0001390478-19-000017
Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$13.32M-$13.32M derivedN/M vs Q4 2017N/M vs Q3 2018
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$4,555,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$13.32M | -$8.79M | $352.00K | -$19.68M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR